Skip to main content

Table 5 Efficacy endpoints: non-inferiority analysis, ANOVA or RMANOVA estimates for group quotients robenacoxib/meloxicam

From: Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial

Variable Estimate (quotient) Standard error 95% Confidence limits P value ANOVA/RMANOVA P value for normality (Shapiro-Wilk)
Lower Upper
Primary endpoint       
1/Modified GCPS score (without B) 1.12 0.08 0.97* 1.29 0.12 <.0001**
1/Unmodified GCPS score (with B) 1.13 0.09 0.96* 1.32 0.13 0.0005**
Secondary endpoints       
1/Pain at rest 1.19 0.16 0.91* 1.55 0.20 <.0001**
1/Pain at palpation/manipulation 1.18 0.18 0.87* 1.58 0.28 0.0049**
1/Global efficacy score 1.08 0.07 0.94* 1.23 0.28 <.0001**
1/Global inflammation score 1.31 0.23 0.93* 1.85 0.12 0.058
1/Owner assessment: demeanor 1.00 0.02 0.95* 1.05 0.96 0.010**
1/Owner assessment: mobility 0.95 0.03 0.89* 1.02 0.17 0.010**
  1. GCPS = Glasgow Composite Pain Scale.
  2. All data were log transformed for the ANOVA/RMANOVA analyses.
  3. Values are reciprocals of scores, thus values >1.00 indicate lower scores (higher efficacy) for robenacoxib versus meloxicam.
  4. * Non-inferiority of robenacoxib to meloxicam shown (lower confidence limit >0.80).
  5. ** Data were not normally distributed after log transformation.